Watermark
Go to Asia edition

Keryx aims for dual listing on high-growth exchanges

  • 28 Jul 2000
WESTLB and Roth Capital should complete the first simultaneous Nasdaq and Aim listing next week. The $46m-$55m IPO of Keryx Biopharmaceuticals was due to close on Tuesday, but has been postponed and will be completed imminently, a banker close to the deal said. The deal ...

Please take a trial or subscribe to access this content.

Contact our subscriptions team to discuss your access: subs@globalcapital.com

Or sign up for a trial to gain full access to the entire site for a limited period.

Free Trial
Log in

Corporate access

To discuss GlobalCapital access for your entire department or company please contact our subscriptions sales team at: subs@globalcapital.com or find out more online here.

Bond Comments

All International Bonds

Rank Lead Manager Amount $m No of issues Share %
View full table
For detailed analysis: Dealogic
  • Last updated
  • Today
1 JPMorgan 227,365.29 1021 8.28%
2 Citi 211,404.92 882 7.70%
3 Bank of America Merrill Lynch 176,375.36 735 6.42%
4 Barclays 164,503.56 674 5.99%
5 HSBC 136,422.24 745 4.97%

Bookrunners of All Syndicated Loans EMEA

Rank Lead Manager Amount $m No of issues Share %
View full table
For detailed analysis: Dealogic
  • Last updated
  • Today
1 BNP Paribas 27,431.07 110 7.85%
2 Credit Agricole CIB 25,823.81 106 7.39%
3 JPMorgan 21,834.93 53 6.25%
4 Bank of America Merrill Lynch 21,382.31 54 6.12%
5 SG Corporate & Investment Banking 16,786.71 79 4.80%

Bookrunners of all EMEA ECM Issuance

Rank Lead Manager Amount $m No of issues Share %
View full table
For detailed analysis: Dealogic
  • Last updated
  • Today
1 Morgan Stanley 7,509.08 37 9.67%
2 JPMorgan 7,363.27 46 9.48%
3 Goldman Sachs 6,842.44 35 8.81%
4 Citi 5,763.97 41 7.42%
5 UBS 4,691.07 23 6.04%